Compare RVSB & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSB | TTRX |
|---|---|---|
| Founded | 1923 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.2M | 116.0M |
| IPO Year | 1997 | N/A |
| Metric | RVSB | TTRX |
|---|---|---|
| Price | $5.62 | $3.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $7.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 36.7K | 20.8K |
| Earning Date | 04-28-2026 | 03-31-2026 |
| Dividend Yield | ★ 1.38% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | $14.55 | N/A |
| P/E Ratio | $32.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.74 | $2.57 |
| 52 Week High | $6.59 | $5.98 |
| Indicator | RVSB | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.20 | 51.33 |
| Support Level | $5.29 | $2.98 |
| Resistance Level | $5.77 | $3.73 |
| Average True Range (ATR) | 0.16 | 0.24 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 70.54 | 77.40 |
Riverview Bancorp Inc is an American savings and loan holding company. The company through its subsidiaries engages in the business of attracting deposits and puts it to use in its market area to originate commercial business. It is organized into two operating segments, Banking Operations performed by the bank and trust and Investment Services performed by the Trust company. The company products and services include checking, saving, money market, mortgage, home equity, consumer, online banking, cash management, and others.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.